Bombay High Court
Issar Pharmaceuticals Private Limited vs Alkem Laboratories on 18 November, 2025
Author: Abhay Ahuja
Bench: Abhay Ahuja
2025:BHC-OS:21384
901. IA 6839-25 in COMEXL 30567-23.doc
IN THE HIGH COURT OF JUDICATURE AT BOMBAY
ORDINARY ORIGINAL CIVIL JURISDICTION
INTERIM APPLICATION NO. 6839 OF 2025
IN
COMMERCIAL EXECUTION APPLICATION (L) NO. 30567 OF 2023
Issar Pharmaceuticals LLP ...Applicant
In the matter between
Issar Pharmaceuticals Pvt. Ltd. ...Applicant/Claimant
V/s.
Alkem Laboratories Ltd. ...Respondent
Ms. Madhavi Nalluri i/b Suraj S. Ghogare,Advocate for the Applicant.
Mr. Arun Siwach with Ms. Priyanka Mitra, Ms Nupur Shah and Ms.
Vidhi Saxena i/b Cyril Amarchand Mangaldas, Advocate for the
Respondent.
CORAM : ABHAY AHUJA, J.
DATE : 18th NOVEMBER, 2025
P.C. :
1. This Interim Application seeks deletion of the name of the
Claimant in the execution proceedings and substitution by Issar
Pharmaceuticals LLP.
2. When the matter is called out, Ms. Nalluri, learned Counsel
appears for the Applicant and submits that pursuant to a Certificate of
Registration of Conversion dated 7th April, 2023 of Issar
Pharmaceuticals Private Limited to Issar Pharmaceuticals LLP, it has
been certified that Issar Pharmaceuticals LLP is registered pursuant to
Section 58(1) of the LLP Act, 2008. Ms. Nalluri submits that in view of
the said certificate dated 7th April, 2023, copy whereof is annexed at
Digitally
signed by
NIKITA
Exhibit A, this Application be allowed.
NIKITA YOGESH
YOGESH GADGIL
GADGIL Date:
20:01:19
+0530
901. IA 6839-25 in COMEXL 30567-23.doc
3. Mr. Siwach, learned Counsel appearing for the Respondent-
Judgment Debtor, submits that despite letters requesting for the
documents and declaration, on the basis of which the conversation of
the private limited company to the limited liability partnership has
happened, no such documents have been furnished. Mr. Siwach submits
that his client, the Judgment Debtor, is concerned as to whether the
rights under the award have been assigned to the Applicant entity.
4. Mr. Siwach submits that earlier on 5 th February, 2024, the Court
taking up petitions under Section 34 of the Arbitration and Conciliation
Act, 1996, has unconditionally stayed the award dated 9 th June, 2023,
which order has been confirmed by the Hon'ble Supreme Court on 6 th
September, 2024. Learned Counsel submits that although the certificate
of Conversion is dated 7th April, 2023, neither before this Court nor
before the Hon'ble Supreme Court this fact had been pointed out that
the Execution Applicant has converted from Private Limited Company
to a Limited Liability Partnership. That this Court before passing any
order may consider the same and keep the rights of the Judgment
Debtor alive.
901. IA 6839-25 in COMEXL 30567-23.doc
5. I have heard the learned Counsel and considered their
submissions. No doubt by a certificate dated 7 th April, 2023, the
Execution Applicant which was a Private Limited Company has been
converted into a Limited Liability Partnership viz. Issar Pharmaceuticals
LLP, which is the Applicant herein, seeking to substitute itself in the
execution proceedings in place of Issar Pharmaceuticals Pvt. Ltd. It is
also observed that the order staying the execution of the award as well
as the order of the Hon'ble Supreme Court confirming the stay are of
dates after the date of the certificate of registration of conversion under
the LLP Act, 2008. As to why this fact was not brought to the notice of
the Courts in the arbitration proceedings is not clear.
6. However, considering the fact that the Ministry of Corporate
Affairs has issued certificate dated 7th April, 2023, in respect of the
conversion of the Execution Applicant to the Applicant herein and
which certificate, to my mind, has not been disputed by the
Respondent-Judgment Debtor except to say that request for the
documents and declaration on the basis of which the Applicant-LLP has
been incorporated have not been supplied despite request. In any
event, the Respondent-Judgment Debtor can always file reply to the
amended proceedings and take up the issues raised above. But that
901. IA 6839-25 in COMEXL 30567-23.doc
should not detain this Court to allow substitution of the Applicant.
7. I am, therefore, of the view that the Interim Application be
allowed in terms of prayer Clause (a), which reads thus:-
"(a) That this Hon'ble Court be pleased to allow the Applicant
to delete the name of the Applicant as "Issar Pharmaceuticals
Private Limited" and replace the same as "Issar
Pharmaceuticals LLP, formerly known as "Issar
Pharmaceuticals Private Limited" in the above captioned
Execution Application and the Affidavit-in-Support thereof as
more particularly recorded in the Schedule anenxed hereto."
8. Let the amendments be carried out to the execution proceedings
within a period of two weeks. Let the amended proceedings be served
upon the Respondent-Judgment Debtor within a period of two weeks
thereafter and an appropriate affidavit of service be filed.
9. The Interim Application is allowed and disposed as above.
10. It goes without saying that upon receipt of the amended
execution proceedings, the Respondent-Judgment Debtor would be
entitled to file a reply, which it may do within a period of four weeks
from the date of service of the amended execution proceedings taking
up inter alia the issues raised before this Court today. Rejoinder in two
weeks thereafter with copy to the other side.
(ABHAY AHUJA, J.)
